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ABSTRACT
The risk of cytomegalovirus (CMV) infection is higher after HLA-matched unrelated donor (URD) than after
HLA-matched related donor (MRD) nonmyeloablative hematopoietic cell transplantation (HCT). We there-
fore investigated factors affecting immune recovery in 94 patients given HCT from MRDs (n  51) and URDs
(n  43) after 2-Gy total body irradiation with or without fludarabine and postgrafting immunosuppression
with mycophenolate mofetil and cyclosporine. CD4 T cells counts remained below normal values during the
first year after HCT in both patient groups. This included abnormally low counts each of naive CD4 T cells
and memory CD4 T cells. Conversely, CD8 T cell counts reached the 10th percentile of normal 6 months after
HCT in MRD and URD recipients. On day 30 after HCT, URD recipients had lower counts of B cells (P 
.02), naive CD4 T cells (P  .04), memory CD4 T cells (P  .005), memory CD8 T cells (P  .005), and
CMV-specific T helper cells (P  .007) than had MRD recipients. This delay in CMV-specific immune
reconstitution translated into increased frequency of CMV antigenemia among URD recipients during the first
100 days after HCT. Older donor age was associated with low counts of naive CD4 T cells on days 180-365
after HCT (P  .003). Further, low numbers of T cells and CD34 cells in the graft and development of acute
graft-versus-host disease were associated with impaired immune recovery of naive CD4 T cells and B cells. In
summary, immunologic recovery was poor the first year after nonmyeloablative conditioning and was delayed
among URD recipients in comparison with MRD recipients. Other factors significantly associated with delayed
immune recovery were advanced donor age, low numbers of CD34 and T cells in the graft, and development
of graft-versus-host disease.
© 2006 American Society for Blood and Marrow Transplantation
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pNTRODUCTION
Allogeneic hematopoietic cell transplantation
HCT) after nonmyeloablative conditioning has been
ncreasingly used as treatment for patients with hema-
ologic malignancies who are ineligible for myeloab-
ative conditioning because of age or comorbidity and
or selected patients with solid tumors. The approach
as relied nearly exclusively on immune-mediated
raft-versus-tumor effects for tumor eradication [1,2].
ain causes of treatment failure after nonmyeloabla-ive conditioning have been relapse and infections H
176ith or without graft-versus-host disease (GVHD) [1],
hich might be partly attributed to a deﬁcit of immu-
ity after HCT (relapse or infection) or a too strong
mmune reaction against the host (GVHD). This em-
hasizes the need for analyses looking at immune
ecovery after nonmyeloablative conditioning.
Several studies have analyzed immunologic recov-
ry after nonmyeloablative or reduced intensity con-
itioning [3-10]. They have included from 15 to 54
atients, most of whom were recipients of grafts from
LA-matched related donors (MRDs). In a previous
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Immunity after Nonmyeloablative Conditioning 1177nalysis, we compared immunologic recovery in recip-
ents of allogeneic granulocyte colony-stimulating fac-
or, mobilized, peripheral blood mononuclear cells
G-PBMCs) from MRDs after nonmyeloablative ver-
us myeloablative conditioning and found higher cy-
omegalovirus (CMV)-speciﬁc T cell activities on days
0 and 90 after HCT among the former, but higher
aive CD4 T cell and naive CD8 T cell counts in the
atter 1 year after HCT [6]. The better immunity
mong nonmyeloablative recipients early after HCT
as due to persistence of T cells from the hosts [6,11],
lthough we attributed the lower counts of naive CD4
cells in nonmyeloablative patients to older recipient
nd/or donor age [6,12-14].
We recently analyzed the effect of unrelated do-
or (URD) status on the incidence and outcomes of
MV infections and found that CMV viremia by
ulture was more common in URD than in MRD
ecipients [15]. This prompted us to compare immu-
ologic recovery in patients given grafts from HLA-
atched URD or MRD after nonmyeloablative con-
itioning. In a second step, we analyzed which other
actors affected immunologic recovery after nonmy-
loablative conditioning, with the aim of identifying
ome possible strategies to improve immune recovery
fter nonmyeloablative HCT.
ETHODS
atients
Among patients given grafts from 10 of 10 HLA-
ntigen matched URDs at the Fred Hutchinson Can-
er Research Center (FHCRC; Seattle, Wash) be-
ween April 2003 and July 2004, 43 consented to
articipate in an institutional review board-approved
tudy evaluating immunologic recovery. Data from
hese 43 patients were compared with those obtained
rom 51 patients given grafts from MRDs after non-
yeloablative conditioning previously reported [6].
onditioning consisted of 2-Gy total body irradiation
lone in 23 MRD recipients [16], and the 28 remain-
ng MRD recipients and all URD recipients were
onditioned with ﬂudarabine (90 mg/m2) followed by
-Gy total body irradiation [17]. Postgrafting immu-
osuppression included mycophenolate mofetil (MMF;
iven at 15 mg/kg 3 times daily for 40 days followed
y a 56-day taper in URD recipients and at 15 mg/kg
times daily for 28 days in MRD recipients) and
yclosporine (CSP; given at 6.25 mg/kg 2 times daily
rom day 3 until day 100, with subsequent taper
hrough day 180 in URD recipients, and given at 6.25
g/kg 2 times daily from day 3 until day 35 or 56,
ith subsequent taper to day 180 in MRD recipients).
esults were analyzed through day 365 after HCT.
atients were removed from analysis at time of graft
ejection or relapse of the underlying malignancy. vDiagnosis and clinical grading of chronic GVHD
ere performed according to established criteria [6].
ecisions for treating acute GVHD were based on the
ttending physicians’ assessment of the severity of
VHD. Initial treatment consisted of prednisolone,
-2 mg/kg per day, with taper started after 14 days. In
ddition, CSP was usually resumed at full dosing.
teroid-refractory acute GVHD (deﬁned as need for a
hird-line therapy for GVHD treatment, with the ﬁrst
ine being GVHD prophylaxis with CSP plus MMF
nd the second being steroids) was treated according
o available investigational protocols or other salvage
egimens. Extensive chronic GVHD was usually
reated with alternate-day prednisolone with or with-
ut CSP.
Standard prophylaxes for Pneumocystis carinii, yeast
nfections, toxoplasmosis, herpesvirus, varicella-zoster
irus, and CMV infections were used among MRD
nd URD recipients [18]. Speciﬁcally, weekly CMV
ntigenemia assays (pp65 antigenemia, blood culture)
ere performed within the ﬁrst 3 months. After day
00, surveillance was recommended weekly to every
ther week to CMV-seropositive recipients or sero-
egative recipients with seropositive donors. Ganci-
lovir (5 mg/kg 2 times daily) was given for any pos-
tive antigenemia and continued until day 100 after
CT; the dose was decreased to 5 mg/kg per day after
week or after a decrease in antigenemia was docu-
ented, whichever occurred later. Ganciclovir was
ubstituted with foscarnet in patients with neutrope-
ia. Patients with chronic GVHD requiring systemic
mmunosuppressive therapy continued prophylaxis for
carinii (using trimethoprim-sulfamethoxazole as
rst-line treatment and dapsone 50 mg 2 times daily as
econd-line treatment) and pneumococcal infections.
Episodes of CMV antigenemia, CMV disease, bac-
eremia, and fungemia were extracted from the elec-
ronic database from the FHCRC. The day of onset of
n infection was deﬁned as the day when the diagnos-
ic test was performed.
uantification of Mononuclear Cell Subsets
Blood specimens were drawn from recipients ap-
roximately 30, 80, 180, and 365 days after transplan-
ation. Mononuclear cells (MNCs) were separated
rom other blood specimens by density gradient
Ficoll) centrifugation, stained with ﬂuorochrome-
onjugated monoclonal antibodies, and then analyzed
y ﬂow cytometry as reported previously [6,19]. Def-
nitions of MNC subsets were performed as previously
escribed [19]. Each absolute MNC subset was calcu-
ated as the absolute MNC count (deﬁned as the sum
f the monocyte count and the absolute lymphocyte
ount determined by a clinical hematology laboratory)
ultiplied by the percentage of the MNC subset di-
ided by 100 [6,19].
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F. Baron et al.1178MV-Specific Assays
Lymphoproliferation upon CMV stimulation (CMV-
CPM). Proliferation of lymphocyte upon stimulation
ith CMV antigens was assessed as previously re-
orted [6]. The relative uptake of thymidine (CPM)
as calculated by subtracting the mean CPM of cells
ncubated with medium alone from the mean CPM of
ells exposed to the CMV antigens. Results were then
xpressed as CPM per 1000 CD4 T cells.
CMV T helper precursors (CMV-LDA). Precursors
f CMV-speciﬁc T helper cells were enumerated by
imiting dilution assay (LDA) as previously described
6,20]. Brieﬂy, 100 L of MNCs were plated in 96-
ell round-bottom plates in 8 serial 2-fold dilutions
tarting from 105 cells per well. For each dilution
evel, 24 replicates received 50 L of CMV antigen,
nd 12 replicates received 50 L of mock antigen
same preparation and dilution as CMV antigen with
ninfected human foreskin ﬁbroblasts). Each well
lso received 104 -irradiated (3300 rad) autologous
NCs (in 50 L) to serve as antigen-presenting cells.
fter 5 days of incubation at 37°C with 5% CO2, the
ells were pulsed with 0.6 Ci 3H and harvested after
8 to 24 hours. Wells were scored positive if the CPM
as 3 times the mean CPM in the corresponding
ock wells. The CMV-speciﬁc T helper precursor
requency was determined using the chi-square mini-
ization technique with a computer program written
y L. Siviuek (provided by C. Orosz; both at Ohio
tate University, Columbus, Ohio) [21,22].
Intracellular cytokine production upon CMV stimulation.
ntracellular cytokine production from CD4 T cells
pon CMV stimulation (CMV-ICC) was assessed as
ollows. First, 0.5 mL of whole blood was cultured in
he presence of a 2:5 cocktail of costimulatory anti-
odies combining anti-CD28 (1 g/mL; Becton Dick-
nson, San Jose, Calif) with anti-CD49d (1 g/mL).
he blood was then unstimulated (negative control),
timulated with CMV lysate (4 g/mL), or stimulated
ith Staphylococcus aureus enterotoxin B SEB (0.05
g/mL), and incubated for 6 hours at 37°C and 5%
O2 with Brefeldin A (10 g/mL; Sigma, St Louis,
o) being added during the last 4 hours of incubation.
fter that, ethylene-diamine tetraacetic acid (20 mM)
as added to the cultures. After a 15-minute incuba-
ion, the blood was lysed with FACS lysing solution
Becton Dickinson) for 10 minutes and washed with
ashing buffer (phosphate buffered saline and bovine
erum albumin 0.5%). Thereafter, cells were perme-
bilized with FACS permeabilizing solution (Becton
ickinson) for 10 minutes, stained with monoclonal
ntibodies (1:1:1 cocktail of CD4 peridinin chloro-
hyll protein, CD69 phycoerythrin, interferon- ﬂu-
rescein isothiocyanate; Becton Dickinson) in the
ark at room temperature for 30 minutes, and then
xed with 1% paraformaldehyde and stored in the fark at 4°C until acquisition. Acquisition of samples
as performed on a FACSCalibur cytometer (Becton
ickinson E1133). Lymphocytes were gated by for-
ard and side scatter, and interferon--producing
ells were enumerated in the CD4CD69 popula-
ion. Samples were analyzed with CellQuest (Becton
ickinson).
Cell Chimerism Analyses
T cells were isolated from the peripheral blood by
ow cytometry using a Vantage SE cytometer (Becton
ickinson) on days 28, 56, 84, 180, and 365 after
CT. Percentages of donor-host chimerism for re-
ipients of sex-mismatched HCT were evaluated by
uorescent in situ hybridization for X and Y chromo-
omes and by polymerase chain reaction-based ampli-
cation of short-tandem repeat or variable-number
andem repeat sequences if recipients and donors were
atched by sex [23,24].
tatistical Analyses
The following tests were used to compare data
rom MRD versus URD recipients. Differences for
ategorical variables were evaluated with chi-square
nd Fisher exact tests, as appropriate. Tests for trend
n 2  3 tables (comparison of underlying disease at
CT and of CMV group between MRDs and URDs)
ere made using the Mantel-Haenszel test. Compar-
sons across recipient age at HCT, donor age, graft
omposition, and MNC subsets after HCT were per-
ormed using the Wilcoxon rank-sum test.
To determine factors affecting the counts of CD4
cell, naive CD4 T cell, CD8 T cell, B cell, natural
iller (NK) cell, CMV-CPM, and CMV-LDA (the
atter 2 only in CMV-seropositive recipients and/or
onors) on days 30, 80, and 180-365 after HCT,
ultivariable linear regression models for the differ-
nt MNC counts at each time point (we elected using
he average between days 180 and 365 for the ﬁnal
ime point because we had data for some patients only
t 1 of those 2 time points and the cell subset counts
ere not statistically different between days 180 and
65) were ﬁt with the SAS Reg procedure (SAS Insti-
ute, Cary, NC) using forward stepwise selection. Se-
ected models were reﬁtted with all patients because
ome patients were excluded in the stepwise selection
ecause of missing values for variables not retained in
he ﬁnal model. Potential factors examined were the
se of ﬂudarabine in the conditioning regimen (for
RD recipients), donor type (URD versus MRD), a
istory of myelosuppressive chemotherapy before
CT, recipient age, donor age, recipient CMV
erostatus, acute and chronic GVHD, and graft con-
ent of T cells and CD34 T cells. Logarithmic trans-
ormation of the responses was used for all models.
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Immunity after Nonmyeloablative Conditioning 1179Cumulative incidences of acute and chronic
VHD and of CMV antigenemia among CMV-sero-
ositive recipients or CMV-seronegative recipients
ith CMV-seropositive donors were calculated using
eath as a competing event. Comparison between
RD and URD was carried out by log-rank test.
ESULTS
atient Characteristics
The characteristics of the 94 patients are listed in
able 1. Brieﬂy, median ages were 52 years among
RD recipients versus 53 years among URD recipi-
nts (P  .44). Median ages were 49 years for MRDs
ersus 31 years for URDs (P	 .0001). Ninety patients
able 1. Patients (n  94)
ecipient age (y), median (range)
onor age (y), median (range)
orrelation (Spearman R) between recipient and donor ages (P)
ale/female recipients
iagnoses, n patients (%)
Acute myeloid leukemia
Myelodysplastic syndrome
Chronic myeloid leukemia
Lymphoma
Chronic lymphocytic leukemia
Multiple myeloma
Solid tumor
No prior myelosuppressive therapy*
MV serostatus before HCT
Recipient positive/donor positive
Recipient positive/donor negative
Recipient negative/donor positive
Recipient negative/donor negative
onditioning regimen
2 Gy TBI
2 Gy TBI  fludarabine (90 mg/m2)
ostgrafting immunosuppression
CSP  MMF bid
CSP  MMF tid
o. cells infused (106/kg), median (range)
CD34 cells
T cells
CD4 T cells
CD8 T cells
B cells
ay-100 cumulative incidence of grade II-IV acute GVHD‡
-Year cumulative incidence of extensive chronic GVHD
MV indicates cytomegalovirus; HCT, hematopoietic cell transpla
nolate mofetil; GVHD, graft-versus-host disease.
Patients who did not receive chemotherapy or received agents as
lators.
Compatibility between patients and donors for HLA-A, -B, and -C
and for -DRB1 and -DQB1 by high-resolution techniques. Th
antigens, whereas 4 pairs were mismatched for a single HLA-A
Nine of 23 patients (39%) given related grafts after 2-Gy TBI onl
ﬂudarabine developed grade II-IV acute GVHD (NS).These patients were all conditioned with ﬂudarabine plus 2 Gy TBI.ad hematologic malignancies, and 4 (3 MRDs and 1
RDs) had solid tumors.
Stem cell source was G-PBMC in all patients. The
edian numbers of CD34 cells and T cells were
0.4  106/kg and 386  106/kg, respectively, for
RD recipients, versus 8.4  106/kg (not signiﬁcant)
nd 294  106/kg (P  .0003), respectively, for URD
ecipients (Table 1).
ngraftment Kinetics in URD versus MRD
We ﬁrst compared donor T cell chimerism levels
mong URD and MRD recipients. As shown in Fig-
re 1A, no signiﬁcant differences in donor T cell
ngraftment kinetics were observed.
HLA-Matched
Related Donors
(n  51)
HLA-Matched†
Unrelated Donors
(n  43) P
52 (35-72) 53 (21-75) .44
49 (37-64) 31 (18-55) <.0001
0.73 (<.0001) 0.14 (.36)
33/18 29/14 .83
4 (8) 12 (28)
5 (10)§ 1 (2)
2 (4)§ 1 (2)
16 (31) 17 (40)
5 (10) 6 (14)
16 (31) 5 (12)
3 (6) 1 (2) .03
8 (16) 3 (7) .22
21 (41) 11 (26)
9 (18) 16 (37)
9 (18) 1 (2)
12 (24) 15 (35) .009
23 (45) 0
28 (55) 43 (100)
51 (100) 0
0 43 (100)
10.4 (1.7-33.8) 8.4 (2.3-26.0) .30
386 (165-760) 294 (102-722) .0003
259 (109-546) 184 (62-378) .0001
117 (37-234) 78 (37-324) .0021
93 (21-203) 48 (12-124) <.0001
47% 67% .03
60% 56% .27
; TBI, total body irradiation; CSP, cyclosporine; MMF, mycophe-
chlorambucil, hydroxyurea, imatinib mesylate, or immunomodu-
ns was assessed by intermediate- and high-resolution DNA typing
ne pairs were matched at the allelic levels for HLA class I and II
), a single HLA-B (n  1), or a single HLA-C (n  1) allele.
s 18 of 28 patients (64%) given related grafts after 2-Gy TBI plusntation
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F. Baron et al.1180mmunologic Recovery in URD versus MRD
T cells. CD4 T cells counts remained below normal
alues during the ﬁrst year after HCT in both patient
roups. This included abnormally low counts each
f naive CD4 T cells, memory CD4 T cells, and
D28CD4 T cells (Figure 2). Interestingly, counts
f naive CD4 T cells were not higher 1 year after
CT (median, 64 cells/L; range, 0-697 cells/L;
 .5) than on day 30 (median, 64 cells/L; range,
-326 cells/L; P  .5). Conversely, CD8 T cell
ounts reached the 10th percentile of normal 6
onths after HCT in MRD and URD recipients.
his was mainly due to the recoveries of memory and
D28CD8 T cells, because counts of naive CD8
cells and CD28CD8 T cells remained below nor-
al up to 1 year after HCT. In comparison with
RD recipients, URD recipients had lower counts of
D4 T cells (P  .056), naive CD4 T cells (P  .04),
emory CD4 T cells (P  .005), CD28CD4 T cells
P  .02), CD28CD4 T cells (P  .005), CD8 T
ells (P  .0004), memory CD8 T cells (P  .005),
D28CD8 T cells (P  .001), and CD28CD8 T
ells (P  .003) on day 30 after HCT. The counts of
cell subsets remained similar in URD and MRD
ecipients 80 to 365 days after HCT.
B cells. B cell counts reached normal values at 1
ear after HCT (Figure 2). This was mainly due to
eneration of new B cells because counts of naive B
ells normalized before counts of memory B cells that
emained low for 1 year after HCT. Compared with
RD recipients, URD recipients had lower counts of
otal B cells (P  .02), naive B cells (P  .03), and
emory B cells (P  .009) on day 30 after HCT.
ounts of B cell subsets were similar in URD and
RD recipients between days 80 and 365 after HCT,
xcept for lower counts of memory B cells on day 80
n URD recipients (P  .04).
NK cells and monocytes. Counts of NK cells and
onocytes reached normal values by day 30 and re-
igure 1. Median donor T cell chimerism levels among HLA-
atched related (solid black line) or unrelated (dashed gray line) trans-
lant recipients. Error bars indicate the 25th and 75th percentiles.ained normal throughout the ﬁrst 1 year after HCT. There were no differences between MRD and URD
ecipients (Figure 2).
CMV-speciﬁc T helper cells. The frequency of
MV-speciﬁc T helper cells was lower in URD than
n MRD recipients on day 30 after HCT as deter-
ined by CMV-CPM (P  .007), CMV-LDA (P 
7), and CMV-ICC (P .02; Figure 3). The frequency
f CMV-speciﬁc T helper cells remained signiﬁcantly
ower in URD than in MRD recipients on day 80 after
CT as determined by CMV-CPM (P  .02). After
hat, the frequency of CMV-speciﬁc T helper cells
as similar between MRD and URD recipients.
nfections in URD versus MRD
The delay in CMV-speciﬁc immune reconstitu-
ion in URD recipients was consistent with increased
requency of CMV infection (and increased use of
reemptive antiviral therapy) among CMV-seroposi-
ive recipients or CMV-seronegative recipients with
MV-seropositive donors given URD (69%) com-
ared with MRD (34%) grafts during the ﬁrst 100
ays after HCT (P .008; Figure 4). This did not lead
o increased CMV disease among URD recipients
1 episode) compared with MRD recipients (2 epi-
odes) during the ﬁrst 100 days after HCT or during
he ﬁrst year after HCT (2 versus 5 episodes), dem-
nstrating that preemptive antiviral therapy was sim-
larly effective in preventing CMV disease in both
roups. Given the statistical association between de-
elopment of grade II-IV acute GVHD and CMV
nfection (hazard ratio, 3.45; P  .002), we developed
multivariable model analyzing the effect of donor
ype on CMV infection, after adjusting for develop-
ent of grade II-IV acute GVHD (considered as a
ime-dependent covariate). In multivariate analysis,
rade II-IV acute GVHD remained signiﬁcantly as-
ociated with increased risk for CMV infection (haz-
rd ratio, 2.75; P  .01), and there was still a sugges-
ion for an independent effect of URD (hazard ratio,
.93; P  .09). Further, among patients who did not
ave grade II-IV acute GVHD, 2 of 18 MRD recip-
ents versus 6 of 8 URD recipients had CMV infection
y day 100 (P  .001), suggesting that URD was
ssociated with increased risks of CMV infection.
Mean values of CMV-CPM on day 30 in patients
ith or without CMV infection before day 100 were
7 
 138 versus 337 
 579 CPM/1000 CD4 T cells
P  .24; Figure 5A). For CMV-LDA, the ﬁgures
ere 214 436 
 532 751 versus 141 528 
 129 102
MV-CD4 T helper cells/L (not signiﬁcant; Figure
B). Interestingly, there was a suggestion for higher
MV-CPM counts among CMV-seropositive pa-
ients receiving grafts from CMV-seropositive donors
han in those given grafts from CMV-seronegative
onors (median, 31.31 versus 19.26 CPM/1000 CD4
cells; P  .1118; Figure 5C). For CMV-LDA, the
ﬁ
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Immunity after Nonmyeloablative Conditioning 1181gures were 44 182 versus 21 780 CMV-CD4
helper cells/L (not signiﬁcant; Figure 5D). Inci-
ence ﬁgures for non-CMV viral infections, bactere-
ias, and invasive fungal infections were not signiﬁ-
antly different between the 2 groups (data not shown).
ultivariable Analysis of Factors Affecting
mmunologic Recovery (Tables 2 and 3)
Fludarabine use. The use of ﬂudarabine was asso-
iated with lower counts of CD4 T cells on days 30
igure 2. Median MNC-subset counts among HLA-matched
ecipients on days 30, 80, 180, and 365 after nonmyeloablative co
*P  .01. Our normal values are shown as horizontal lines (thi
edian). Days after transplantation are shown on all x axes. On a
mmunoglobulin.nd 80 (P  .009 and P  .010, respectively), lower iounts of naive CD4 T cells on day 80, and lower
ounts of B cells on day 80 after HCT.
Donor type. Multivariable linear regression models
howed that URD recipients had signiﬁcantly lower
ounts of naive CD4 T cells (P  .0005) and total
D8 T cells (P  .0003) on day 30 after HCT and
ower counts of CMV-CPM on days 30 and 80 after
CT (P  .001 and P  .008, respectively). The
ay-30 counts of CD4 T cells were no longer signif-
cantly different between MRD and URD recipients
(solid black line) or unrelated (dashed gray line) transplant
ning. Error bars indicate the 25th to 75th percentiles. *P  .05;
line for the 10th and 90th percentiles and dashed line for the
s, values for cell counts are per microliter of blood. Ig indicatesrelated
nditio
ck solid
ll y axen multivariable analysis.
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F. Baron et al.1182Previous chemotherapy. Administration of chemo-
herapy before HCT did not affect cell subset recov-
ries at any time point after HCT.
Recipient and donor age. Advanced donor age (ana-
yzed as a continuous variable) was associated with low
ounts of naive CD4 T cells on days 30 (P .001) and
80-365 (P  .003) after HCT. No signiﬁcant effect
f recipient age was observed in the multivariable
nalyses. To further study the effect of donor age on
aive CD4 T cell recovery, we analyzed factors affect-
ng naive CD4 T cell recovery among URD recipients
nly, because there was no correlation between recip-
igure 3. A-C, Median CMV-speciﬁc CD4 T cell counts and/or
unction among HLA-matched related (solid black line) or unre-
ated (dashed gray line) transplant recipients on days 30, 80, 180,
nd 365 after nonmyeloablative conditioning. Error bars indicate
he 25th to 75th percentiles. *P  .05; **P  .01. Days after
ransplantation are shown on all x axes.ent and donor ages in this group. Results are pre- aented in Table 3 and showed that advanced donor age
as associated with lower counts of naive CD4 T cells
n days 30 and 80 after HCT, although the associa-
ion was not statistically signiﬁcant (probably because
f the relatively small number of patients studied) on
ays 180-365.
Recipient CMV serostatus. Recipient CMV seropos-
tivity was associated with higher counts of CD8
cells on days 80 (P  .02) and 180-365 (P  .06)
fter HCT and with low counts of naive CD4 T cells
P  .0346) on days 180-365 after HCT.
Graft composition. The numbers of T cells infused
orrelated with the number of CD34 cells (Spearman
 0.33; P  .002), CD4 T cells (R  0.92; P 	
0001), CD8 T cells (R 0.81; P	 .0001), and B cells
R  0.57; P 	 .0001) infused. There was also
correlation between the numbers of CD34 and
cells infused (R  0.40; P  .0002). Large numbers
f CD34 cells among G-PBMCs were associated with
igh counts of naive CD4 T cells on day 80 (P  .01),
igh counts of B cells on day 30 (P  .02), and a trend
oward higher NK cell counts on day 30 (P  .09).
arge numbers of T cells transplanted were associated
ith high counts of B cells on days 30 (P .04) and 80
P  .002) after HCT, with high levels of CMV-
CPM on days 80 (P  .008) and 180-365 (P  .01)
fter HCT and with high numbers of CMV-LDA on
ays 180-365 after HCT (P  .02). There were no
igniﬁcant associations between donor age and num-
ers of CD34 and B cells, CD4 T cells, CD8 T cells,
r B cells infused.
Graft-versus-host disease. Acute GVHD was associ-
ted with low counts of naive CD4 T cells on day 80
fter HCT (P  .0099) and with low counts of B cells
n days 80 (P  .08) and 180-365 (P  .03) after
CT. Further, acute GVHD was suggestively associ-
ted with lower counts of CMV-CPM on days 80
P  .02) and 180-365 (P  .03) after HCT in uni-
ariate analysis, although these associations were no
onger signiﬁcant in multivariable analysis. No signif-
cant associations between extensive chronic GVHD
igure 4. Day-100 cumulative incidence of CMV antigenemia
mong URD versus MRD recipients (P  .008).
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Immunity after Nonmyeloablative Conditioning 1183nd MNC subsets counts were observed. When anal-
ses were restricted to URD recipients, acute GVHD
as associated with lower counts of naive CD4 T cells
n day 80, whereas acute (P  .01) and chronic (P 
igure 5. A, B, Day-30 CMV-CPM (A; P  .24) and CMV-LDA
00. C, D, Day-30 CMV-CPM (C; P  .11) and CMV-LDA
MV-seronegative versus CMV-seropositive donors. Horizontal li
able 2. Multivariable Analyses of Factors Affecting Immune Recovery
Cell Subset
Days after
HCT Facto
D4 T cell 30 Fludarabine use (P  .009); s
GVHD (P  .067)
80 Fludarabine use (P  .010); s
180 and 365* MRD vs URD (P  .035)
aive CD4 T cell 30 URD vs MRD (P  .0005); ad
80 Small number of CD34 cells
fludarabine use (P  .032)
180 and 365 Advanced donor age‡ (P  .0
D8 T cell 30 URD vs MRD (P  .0003)
80 Recipient CMV seronegative
180 and 365 Recipient CMV seronegative
cell 30 Small number of CD34 cells
(P  .039)
80 Fludarabine use (P  .063); s
GVHD (P  .086)
180 and 365 Grade II-IV acute GVHD (P 
MV-CPM 30 URD vs MRD (P  .001)
80 URD vs MRD (P  .008); sm
180 and 365 Small number of T cells tran
MV-LDA 180 and 365 Small number of T cells tran
CT indicates hematopoietic cell transplantation; CMV indicate
matched related donor; GVHD, graft-versus-host disease; CP
Other factors assessed were patient age, prior myelosuppressive che
For lymphocyte subset counts, blood from 51, 52, and 45 patients
studies, analysis were restricted to CMV-seropositive patients
Thirty-three of the 66 patients were tested on day 30, 36 on daContinuous linear variable.06) GVHD each correlated with lower counts of
aive CD4 T cells on days 180-365 after HCT.
Day-28 T cell chimerism. High day-28 donor T cell
himerism levels (analyzed as a continuous variable)
.53) counts in patients without or with CMV infection before day
 .86) counts in CMV-seropositive recipients given grafts from
resent medians.
onmyeloablative Conditioning*†
sociated with Lower Cell Subset Counts
mber of CD34 cells transplanted‡ (P  .019); grade II-IV acute
mber of CD34 cells transplanted‡ (P  .022)
donor age‡ (P  .001)
anted‡ (P  .011); grade II-IV acute GVHD (P  .010);
tient CMV seropositive (P  .035)
19)
63)
anted‡ (P  .022); small number of T cells transplanted‡
mber of T cells transplanted‡ (P  .002); grade II-IV acute
ber of T cells transplanted‡ (P  .024)
d‡ (P  .013)
d‡ (P  .022)
egalovirus; URD, HLA-matched unrelated donor; MRD, HLA-
tive uptake of thymidine; LDA, limiting dilution assay.
apy or not, day-28 T cell chimerism, and extensive chronic GVHD.
lyzed on days 30, 80, and 180-365, respectively. For CMV-speciﬁc
V-seronegative patients with CMV-seropositive donor (n  67).
nd 25 on days 180-365, respectively.(B; P 
(D; Pafter N
r(s) As
mall nu
mall nu
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03); pa
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F. Baron et al.1184ere associated with high counts of NK cells on day
0 after HCT.
ISCUSSION
Reconstitution of T cells after allogeneic HCT
ccurs through new generation from transplanted he-
atopoietic stem cells (thymo-dependent pathway) or
hrough peripheral expansion of T cells contained in
he grafts (thymo-independent pathway) [25-28].
fter myeloablative conditioning, neo-generation of
cells has been minimal during the ﬁrst 3 months
fter HCT [29], and naive T cells during the ﬁrst 6
onths after HCT have been largely offspring of
aive T cells infused with the grafts [30]. Factors
other than graft composition) associated with faster T
ell regeneration after myeloablative conditioning
ave been younger patient age and absence of GVHD
26,31-33]. After autologous HCT, thymic rebound,
s documented by changes in thymic sizes and T cell
eceptor excision circle (TREC) levels, has been seen
n approximately 80% of individuals younger than 40
ears, in 50% of those 40 to 50 years of age, but in
nly 10% of patients older than 50 years [12]. Further,
hymic output decreases by 95% between 25 and 65
ears of age in healthy individuals [13]. These obser-
ations predicted that T cell immune recovery might
e particularly slow after nonmyeloablative condition-
ng, because this therapy is mainly offered to older
atients. In a previous report, we showed that (older)
onmyeloablative recipients had lower counts of naive
D4 T cells and naive CD8 T cells than did (younger)
yeloablative recipients 1 year after HCT [6].
We recently showed that persistence of host im-
unity translated into delayed CMV disease after
onmyeloablative HCT with MRD [6]. Because pa-
ients given grafts from URD after nonmyeloablative
onditioning had a higher incidence of CMV infection
able 3. Multivariable Analyses of Factors Affecting Naive CD4 T
ell Recovery after URD Nonmyeloablative HCT*
Days after HCT
Factor(s) Associated with Lower Cell
Subset Counts
0 Advanced donor age (P  .03)
0 Advanced donor age (P  .005); low donor
T cell chimerism levels (P  .055); acute
GVHD (P  .053)
80 and 365† Acute GVHD (P  .012); extensive chronic
GVHD (P  .056)
CT indicates hematopoietic cell transplantation; GVHD, graft-
versus-host disease.
Other factors assessed were patient age, prior myelosuppressive
chemotherapy or not, day-28 T cell chimerism, grade II-IV
acute GVHD, number of CD34 and T cells transplanted, re-
cipient cytomegalovirus seropositivity, and recipient age.
Continuous linear variable.han did those given grafts from MRD [15], we ana- iyzed whether this was due to a relative deﬁcit of
mmunity among URD versus URD recipients. Fur-
her, we investigated which other factors affected the
inetics of recovery after nonmyeloablative condition-
ng.
Our study showed a delayed immune recovery
mong URD recipients compared with MRD recipi-
nts. This could have been due to several factors.
irst, MMF was given at higher doses and was ex-
ended in URD recipients. Further, all URD recipi-
nts versus 55% of MRD recipients received ﬂudara-
ine conditioning. This might explain the lower CD4
cell counts on day 30 after HCT, given the pro-
ound CD4 depleting effect of ﬂudarabine and the
tatistical association between ﬂudarabine and lower
D4 T cell counts on day 30 after HCT in the present
tudy. However, ﬂudarabine had no signiﬁcant effect
n other cell subset counts. Other possible explana-
ions for the lower cell counts in URD recipients on
ay 30 after HCT included the greater degrees of
inor histocompatibility antigen disparities between
nrelated donors and recipients that might have af-
ected immune recovery.
The delay in (CMV-speciﬁc) immune recovery
as likely the reason for a higher incidence of CMV
ntigenemia in URD recipients (Figure 4). This was in
greement with previous reports showing higher inci-
ences of CMV reactivation in URD versus MRD
ecipients after nonmyeloablative conditioning [15],
nd that CMV-speciﬁc immunity predicted CMV
nfection after myeloablative conditioning [34-37].
RD status had an effect early after HCT on the
uantity of CMV-speciﬁc T helper cells (Figure 3B)
nd on the reactivity on a per-cell basis throughout
he observation period (Figure 3A). Of note, the delay
n CMV-speciﬁc immune reconstitution did not lead
o increased CMV disease among URD recipients,
emonstrating that preemptive antiviral therapy was
imilarly effective in preventing CMV disease in the 2
atient groups.
Transplanting a high number of T cells was asso-
iated with high counts of CMV-speciﬁc T helper
ells on days 180-365 after HCT. This ﬁnding is
onsistentwith previous data showing improvedCMV-
peciﬁc immune recovery in patients given G-PBMC
nstead of marrow grafts, which contained a log less T
ells [38].
The ﬁndings of low naive CD4 T cell and B cell
ounts and lower counts of CMV-CPM in patients
ith acute GVHD were not surprising and conﬁrmed
revious observations in patients given myeloablative
onditioning [26,38,39]. In part, this might reﬂect the
dverse effect of high-dose corticosteroid treatment of
VHD on neo-generation and peripheral expansion
f T and B cells [38,40,41].
Another important ﬁnding was that counts of na-
ve CD4 and CD8 T cells and counts of CD28CD4
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Immunity after Nonmyeloablative Conditioning 1185nd CD28CD8 T cells remained below normal val-
es for up to 1 year after HCT. In addition, counts of
aive CD4 T cells on day 365 were similar to those on
ay 30, suggesting that neo-generation of T cells was
eak during the ﬁrst year after HCT, and/or that the
ife span of naive T cells was short, perhaps because of
VHD [42]. This ﬁnding was not surprising given the
ge-related thymic atrophy [13]; 75% of our patients
ere 44 years of age and 25% were 59 years.
urther, results are in agreement with a report on data
rom 15 patients given nonmyeloablative conditioning
hat showed that the number of TREC-positive cells
radually decreased during the ﬁrst 6 months after
CT, consistent with the notion that thymic T cell
utput was weak [7].
Older donor age was associated with low counts of
aive CD4 T cells on days 180-365 after HCT, in
greement with observations in mice showing an
nverse correlation between recovery of naive CD4 T
ells and donor age after HCT [14] and with data in
umans showing higher TREC frequencies in age-
nd GVHD-matched young adults given allogeneic
ord blood versus allogeneic bone marrows, despite
uch lower numbers of CD34 cells and T cells
ransplanted [43]. Possible explanations for the effect
f donor age on immune recovery included the de-
reased frequency of prethymic T cell progenitors
ithin hematopoietic stem cells with aging, the 0.5%
ecrease per year of the numbers of naive T cells
deﬁned as CD31CD4 T cells) in healthy individ-
als, and the decreased proliferation of naive T cells in
lder individuals [13,44-46].
In conclusion, immunologic recovery was delayed
mong URD recipients compared with MRD recipi-
nts. Other factors signiﬁcantly affecting immune
ecovery included donor age, numbers of CD34 and T
ells in the graft, and development of acute GVHD.
electing younger donors whenever possible might
mprove immunologic recovery after nonmyeloabla-
ive conditioning.
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